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Abstract
Sphingosine 1-phosphate (S1P) is a bioactive sphingolipid that plays
an important proinflammatory role in asthmatic airways.
Corticosteroids are first-line antiinflammatories in asthma; however,
their repressive effects on S1P-induced cytokine secretion have not
been investigated. To address this, our in vitro study reveals the
molecularmechanisms bywhich corticosteroids inhibit S1P-induced
IL-6 expression in the pivotal immunomodulatory cell type, airway
smooth muscle (ASM). We first uncover the cellular signaling
pathways responsible: S1P activates a cyclic adenosine
monophosphate/cAMP response-element-binding protein (CREB)/
CRE-dependent pathway to induce IL-6 transcription, concomitant
with stimulation of the mitogen-activated protein kinase (MAPK)
superfamily and downstream mitogen and stress-activated protein
kinase 1 (MSK1) and histone H3 phosphorylation. In this way, S1P
stimulates parallel signaling pathways to induce IL-6 secretion via
CRE-driven transcription of the IL-6 gene promoter in a relaxed
chromatin environment achieved through histone H3
phosphorylation. Second, we investigated how corticosteroids
mediate their repressive effects. The corticosteroid dexamethasone
inhibits S1P-induced IL-6 protein secretion and mRNA expression,
but CREB/CRE transrepression, inhibition of IL-6 mRNA stability,
or subcellular relocation of MSK1 were not responsible for the
repressive effects of dexamethasone. Rather, we show that
dexamethasone rapidly induces up-regulation of the MAPK
deactivator MAPK phosphatase 1 (MKP-1) and that MKP-1 blocks
the MAPK-driven activation of MSK1 and phosphorylation of
histone H3. This was confirmed by treatment with triptolide, an
inhibitor of MKP-1 up-regulation, where repressive effects of
corticosteroids were reversed. Our study reveals the molecular
mechanism underlying the antiinflammatory capacity of
corticosteroids to repress proinflammatory functions induced by the
potent bioactive sphingolipid S1P in the lung.
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Clinical Relevance
Sphingosine 1-phosphate (S1P) is a bioactive sphingolipid that
plays an important proinflammatory role in asthmatic airways.
Corticosteroids are first-line antiinflammatories in asthma;
however, their repressive effects on S1P-induced cytokine
secretion have not been investigated to date. To address this,
our in vitro study reveals the molecular mechanisms by which
corticosteroids inhibit S1P-induced IL-6 expression in the
pivotal immunomodulatory cell type airway smooth muscle.
Sphingosine 1-phosphate (S1P) is
a bioactive sphingolipid that is elevated in
the airways of patients with asthma (1).
Recent evidence in mouse models of
asthma have demonstrated that S1P plays
a crucial role in the development of airway
inflammation (2) and hyperresponsiveness
(3); thus, S1P-mediated pathways have
emerged as legitimate targets for drug
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discovery to combat asthma. The regulation
of the S1P-induced proasthmatic
phenotype by the first-line
antiinflammatory medications
(i.e., corticosteroids), has not been
explored. Thus, an understanding of the
molecular mechanisms that underlie S1P-
induced proinflammatory effects and the
regulation of these functions by antiasthma
drugs is important.
In 2001 we demonstrated that S1P
modulates myriad airway smooth muscle
(ASM) functions that promote
inflammation and remodeling in asthma (1).
S1P increased the cytokine IL-6 in
a concentration-dependent manner via
activation of S1P receptors linked to
adenylate cyclase. However, the
mechanisms of IL-6 transcriptional up-
regulation are unknown, and we need to
demonstrate the antiinflammatory capacity
of the corticosteroids against this potent
bioactive sphingolipid in the lung.
Furthermore, understanding the molecular
mechanisms by which corticosteroids
perform their antiinflammatory actions will
yield crucial information for further
refinement of corticosteroid regimens in
pharmacotherapy.
Our previous work (1) demonstrated
that S1P-induced secretion of IL-6 occurred
via cyclic adenosine monophosphate
(cAMP) accumulation. We have also
recently shown that S1P activates members
of the mitogen-activated protein kinase
(MAPK) (p38 MAPK, p42/p44 MAPK
[ERK] and c-Jun N-terminal kinase [JNK])
superfamily in a cell-type specific manner
(4) and that S1P-induced IL-6 secretion is
ERK- and p38 MAPK-dependent (4).
Herein we extend our earlier studies to
uncover the parallel cellular signaling
pathways stimulated by S1P. We show that
(1) a cAMP/cAMP response-element-
binding protein (CREB)/CRE-dependent
pathway is responsible for S1P-induced IL-
6 transcription (i.e., S1P rapidly and
robustly leads to phosphorylation of CREB
at Ser133 and the CRE binding site of the IL-
6 promoter, but not AP-1, C/EBP, or NF-
kB, is essential for S1P-induced IL-6
transcription) and (2) S1P activates the
MAPK superfamily in a temporally specific
manner. ERK and p38 phosphorylation
then contributes to activation of the
downstream mitogen and stress-activated
protein kinase 1 (MSK1) (via
phosphorylation at Thr581) to induce
phosphorylation of histone H3 at Ser10. It is
this latter pathway that is targeted for
repression by corticosteroids. We show that
MAPK-driven phosphorylation of histone
H3 is repressed by corticosteroid-mediated
up-regulation of the endogenous MAPK
deactivator mitogen-activated protein
kinase phosphatase 1 (MKP-1).
Materials and Methods
ASM Cell Culture
Human bronchi were obtained from
patients undergoing surgical resection for
carcinoma or from lung transplant donors
in accordance with procedures approved by
the Sydney South West Area Health Service
and the Human Research Ethics Committee
of the University of Sydney. ASM cells were
dissected, purified, and cultured as
previously described (5). A minimum of
three different ASM primary cell lines were
used for each experiment.
Chemicals
S1P (Biomol) was purchased through Enzo
Life Sciences (Exeter, UK). Unless otherwise
specified, all chemicals were from Sigma-
Aldrich (St. Louis, MO).
ELISA
Cell supernatants were collected and stored
at 2208C for later analysis by ELISA. IL-6
ELISAs were performed according to the
manufacturer’s instructions (BD
Biosciences Pharmingen, San Diego, CA).
Transfection
ASM cells were transfected with the parental
IL-6 promoter construct, pIL-6-luc 651,
a pGL3 luciferase reporter vector (Promega,
Madison,WI) containing a 651-bp fragment
of the human IL-6 gene promoter (kindly
provided by Oliver Eickelberg, Ludwig-
Maximilians-Universität and Helmholtz
Zentrum München, Germany) [6], with
permission from Shigeru Katamine,
Nagasaki University, Nagasaki, Japan [7]);
a series of constructs in which the
consensus binding sites for AP-1, C/EBP-b,
and NF-kB had been inactivated by site-
directed mutagenesis (pIL-6-luc 651 DAP-
1, pIL-6-luc 651 DC/EBP-b, or pIL-6-luc
651 DNF-kB, respectively) (6); or a 59-
deletion construct (pIL-6-luc158) in which
the AP-1 and the CRE binding sites had
been deleted (8). Transient transfection of
ASM cells was performed using
Lipofectamine 2000 (Invitrogen Corp.,
Carlsbad, CA) as previously described (9).
Cells were harvested, and luciferase and
b-galactosidase activities were assessed
according to manufacturer’s instructions
(Promega). Data are presented as
normalized luciferase activity relative to
vehicle-treated cells (expressed as fold
difference).
Details about real-time RT-PCR,
mRNA stability, and Western blotting are
provided in the online supplement.
Small Interfering RNA Knock Down
ASM cells were transiently transfected
using nucleofection with 1 mg MSK1-
specific SMART pool small interfering
RNA (siRNA), consisting of a pool of four
individual siRNA from Dharmacon
(Lafayette, CO) or a scrambled control,
using the methods established in our
previous publication (10). Briefly, ASM
cells were transfected with the
Nucleofector (Amaxa, Koln, Germany)
using the basic kit for primary smooth
muscle cells with the manufacturer’s
optimized protocol of P-024. ASM cells
were plated for 16 hours after transfection
before being growth-arrested for a further
24 hours. Cells were then treated in
accord with the experimental protocol
before supernatants were removed for IL-6
protein measurement by ELISA, and
lysates were used for MSK1 or MKP-1
Western blotting.
Translocation
Cytoplasmic and nuclear protein
extraction was performed using a NE-PER
nuclear and cytosolic extraction kit
(Thermo Fisher Scientific, Rockford, IL)
according to the manufacturer’s
instructions. MSK1 was quantified by
Western blotting and compared with
a-tubulin and lamin A/C (rabbit
polyclonal IgG antibodies; Cell Signaling
Technology, Danvers, MA) as loading
controls for the cytosolic and nuclear
fractions, respectively.
Statistical Analysis
Statistical analysis was performed using
Student’s unpaired t test, one-way ANOVA,
Fisher’s post hoc multiple comparison test
or two-way ANOVA, then Bonferroni’s
post-test. P values less than 0.05 were
sufficient to reject the null hypothesis for all
analyses.
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Results
S1P Induces IL-6 Secretion from ASM
Cells via Transcriptional Regulation of
IL-6 Gene Expression
To confirm our earlier report of
proinflammatory effects of S1P on ASM
synthetic function (1), growth-arrested
ASM cells were treated with vehicle or S1P
(1 mM) for 24 hours, and secreted IL-6 was
measured by ELISA. S1P induces
a significant increase in IL-6 secretion (P ,
0.05) (Figure 1A). This increase in IL-6
secretion from ASM cells in response to
S1P occurred via transcriptional regulation
(Figure 1B); S1P (1 mM) induced a 2.9 6
0.4-fold increase in IL-6 promoter activity
in ASM cells transiently transfected with
pIL-6-luc 651 (P , 0.05), a pGL3 luciferase
reporter vector containing a 651-bp
fragment of the human IL-6 gene promoter.
Dexamethasone Inhibits S1P-Induced
IL-6 Protein Secretion and mRNA
Expression at the Transcriptional, but
Not Posttranscriptional, Level of
Gene Expression
We examined the inhibitory efficacy of the
corticosteroid dexamethasone on S1P-
induced IL-6 protein secretion and mRNA
expression. Growth-arrested ASM cells were
pretreated with vehicle or with increasing
concentrations of dexamethasone (0.0001–1
mM) and stimulated for 24 hours with S1P
(1 mM), and IL-6 protein secretion was
measured by ELISA. Dexamethasone
inhibited S1P-induced IL-6 protein
secretion in a concentrated-related manner
(P , 0.05) (Figure 2A). S1P induced
a significant 12.3 6 2.0-fold increase in IL-
6 mRNA expression (P, 0.05) (Figure 2B).
Moreover, S1P-induced IL-6 mRNA
expression was significantly inhibited by
100 nM dexamethasone (P , 0.05)
(Figure 2B), where dexamethasone
pretreatment reduced S1P-induced IL-6
mRNA expression 1.9 6 0.3-fold.
After demonstrating that
dexamethasone inhibits S1P-induced IL-6
protein secretion and mRNA expression, we
examined whether this inhibition occurred
at the transcriptional or posttranscriptional
level. We transfected ASM cells with the
pIL-6-luc 651 promoter and pretreated with
vehicle or 100 nM dexamethasone, before
stimulation for 24 hours with S1P
(Figure 2C). Dexamethasone significantly
inhibited S1P-induced IL-6 promoter
activity (P , 0.05), reducing the luciferase
activity to levels equivalent to those
observed in vehicle-treated cells. We next
examined whether dexamethasone acts at
the posttranscriptional level to reduce the
stability of S1P-induced IL-6 mRNA
transcript. Growth-arrested ASM cells were
pretreated for 1 hour with dexamethasone
before stimulation with S1P for 9 hours.
Transcription was then halted using
actinomycin D, and real-time RT-PCR was
used to measure IL-6 mRNA degradation
over time to determine the kinetics of
decay. We found that pretreatment of ASM
cells with dexamethasone had no effect on
the stability of the S1P-induced IL-6
transcript (Figure 2D). That is, the decay
kinetics of the S1P-induced IL-6 transcript
induced in the presence (20.0933 6
0.0420; t1/2=7.4 h) or absence (20.0529 6
0.0231; t1/2=13.1 h) of dexamethasone were
not significantly different (results expressed
as decay constant [k] and half-life [h]; P .
0.05).
S1P-Induced IL-6 Transcriptional
Regulation Is CRE Dependent, but
Dexamethasone Does Not Inhibit
S1P-Induced CREB Phosphorylation
We previously demonstrated that S1P-
induced secretion of IL-6 is achieved via
a S1P receptor–mediated increase in cAMP
accumulation (1). We now extend our
earlier studies to examine the
transcriptional regulation of IL-6 by S1P
using a series of luciferase reporter vectors
containing full-length, mutated, or
truncated constructs of a 651-bp fragment
of the human IL-6 gene promoter. ASM
cells were transiently transfected with the
parental construct pIL-6-luc 651 or with
a series of constructs in which the
consensus binding sites for AP-1, C/EBP,
and NF-kB have been inactivated by site-
Figure 1. Sphingosine 1-phosphate (S1P) induces IL-6 secretion from airway smooth muscle (ASM)
cells via transcriptional regulation of IL-6 gene expression. (A) Growth-arrested ASM cells were
treated with vehicle or S1P (1 mM) for 24 hours. Secreted IL-6 was measured by ELISA. (B) ASM
cells were transfected with pIL-6-luc 651, a pGL3 luciferase reporter vector containing a 651-bp
fragment of the human IL-6 gene promoter, and then growth-arrested and treated with vehicle or
S1P (1 mM) for 24 hours. Cells were harvested, and luciferase and b-galactosidase activities were
assessed. Data represent normalized luciferase activity relative to vehicle-treated cells (expressed as fold
difference). Statistical analysis was performed using the Student’s unpaired t test. *Significant effect of
S1P (P , 0.05). Data are mean 1 SEM values from (A) n = 12 and (B) n = 22 primary ASM cell lines.
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directed mutagenesis or a 59-deletion
construct (pIL-6-luc158) in which the AP-1
and CRE binding sequences have been
deleted. Mutations in the AP-1, C/EBP, or
NF-kB binding sequences had no
significant effect on S1P-induced IL-6
promoter activity (Figure 3A). However, in
cells transfected with pIL-6-luc158, a 59
truncated version of the parental construct
deficient in AP-1 and CRE binding
sequences, S1P-induced IL-6 promoter
activity was significantly reduced (P ,
0.05) (Figure 3A). Taken together, these
results suggest that binding to CRE, but not
to AP-1, NF-kB, or C/EBP, mediates S1P-
induced IL-6 gene expression in ASM via
a cAMP-mediated pathway.
Because we have shown that S1P
transcriptional regulation occurred via
activation of the CRE region of the IL-6
promoter (Figure 3A), we wished to
demonstrate S1P-induced phosphorylation
of the transcription factor CREB and to
examine the possibility that the mechanism
of inhibition by dexamethasone was via
repression of S1P-induced CREB activation.
Growth-arrested ASM cells were pretreated
for 1 hour with vehicle or 100 nM
dexamethasone and then stimulated with
S1P (1 mM) for up to 1 hour. S1P rapidly
phosphorylates CREB (at Ser133) by 5
minutes, and the degree of phosphorylation
was sustained for up to 1 hour (Figure 3B).
There was no difference in the temporal
kinetics of S1P-induced CREB
phosphorylation in cells pretreated with
dexamethasone compared with those
pretreated with vehicle alone.
Taking the results from this section
together, these data demonstrate (1) that
S1P induces cAMP (1), (2) that S1P rapidly
and robustly phosphorylates the
transcriptional factor CREB at Ser133, and
(3) that the CRE binding site of the IL-6
promoter is essential for S1P-induced IL-6
transcriptional regulation. However,
dexamethasone does not inhibit S1P-
induced CREB phosphorylation.
S1P-Induced MAPK Phosphorylation
Is Inhibited by Dexamethasone-
Induced MKP-1
S1P activates members of the MAPK
superfamily in a temporally specific manner
(4). We now wished to investigate whether
the repressive action of corticosteroids on
S1P-induced IL-6 occurs in a similar
manner to that recently observed for TNF-
a–induced IL-6 (11) and IL-1b–induced
Figure 2. Dexamethasone inhibits S1P-induced IL-6 protein secretion and mRNA expression at the
transcriptional, but not posttranscriptional, level of gene expression. (A) Growth-arrested ASM cells
were pretreated for 1 hour with vehicle or dexamethasone (0.0001–1 mM) and then stimulated for
24 hours with S1P (1 mM). Secreted IL-6 was measured by ELISA. Statistical analysis was performed
using one-way ANOVA followed by Fisher’s post hoc multiple comparison test. *Significant effect
of dexamethasone (P , 0.05). Data are mean 1 SEM values from n = 12 primary ASM cell lines. (B)
Growth-arrested ASM cells pretreated for 1 hour with vehicle or 100 nM dexamethasone were
stimulated with S1P (1 mM) for 9 hours, and IL-6 mRNA expression was quantified by real-time RT-
PCR (results expressed as fold difference compared with vehicle-treated cells). (C) ASM cells
transfected with pIL-6-luc 651 were pretreated for 1 hour with vehicle or 100 nM dexamethasone
(Dex) and then stimulated for 24 hours with S1P (1 mM). Data represent normalized luciferase activity
relative to vehicle-treated cells (expressed as fold difference). Statistical analysis was performed
using the Student’s unpaired t test. *Significant effect of dexamethasone (P, 0.05). Data are mean1
SEM values from (B) n = 3 and (C) n = 9 primary ASM cell lines. (D) Growth-arrested ASM cells
pretreated for 1 hour with vehicle (open squares) or 100 nM dexamethasone (closed squares) were
stimulated with S1P (1 mM) for 9 hours and then washed and incubated with actinomycin D (5 mg/ml)
to inhibit further transcription. Total RNA was extracted after 0, 1, 2, 3, 6, 9, and 12 h, and IL-6
mRNA expression was quantified. Results are expressed as % mRNA remaining over time (dashed
lines represent nonlinear regression of the % mRNA remaining vs. time after actinomycin D) (41). Data
are mean 6 SEM values from n = 3 primary ASM cell lines.
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growth-related oncogene protein a (11)
via corticosteroid-induced up-regulation
of the endogenous MAPK deactivator,
MKP-1. When ASM cells were pretreated
for 1 hour with dexamethasone before S1P
stimulation, up-regulated MKP-1 was
evident at 30 and 60 minutes (Figure 4A).
Densitometric analysis demonstrated that
dexamethasone significantly enhances
S1P-induced MKP-1 protein up-regulation
over time (P , 0.05) (Figure 4B). The
increase in MKP-1 after corticosteroid
treatment mirrored the decrease in S1P-
induced p38 MAPK phosphorylation at 30
minutes, suggesting that dexamethasone-
induced MKP-1 shortens the temporal
phosphorylation of MAPKs in response to
S1P. This was confirmed by densitometry,
where dexamethasone significantly
inhibited S1P-induced p38 MAPK
(Figure 4C) and ERK (Figure 4D)
phosphorylation (P , 0.05). Although
S1P-induced JNK phosphorylation
appears on the Western blot (Figure 4A) to
be inhibited by dexamethasone
pretreatment at 30 minutes, this difference
was not statistically significant (Figure 4E).
Dexamethasone Inhibits S1P-Induced
Activation of MSK1 and Induction of
Histone H3 Phosphorylation
Because S1P-induced MAPK
phosphorylation was inhibited by
dexamethasone (mirrored by up-regulation
of MKP-1), we hypothesized that the
mechanism responsible for the inhibition of
S1P-induced IL-6 by dexamethasone was
the MKP-1–mediated repression of the
MAPK pathways responsible for cytokine
secretion. To address this further, we
focused on the p38 MAPK and ERK
signaling pathways because these MAPK
family members are responsible for S1P-
induced IL-6 secretion in ASM cells (4). We
examined the activation of two important
downstream phosphoproteins, MSK1 and
histone H3. MSK1 (mitogen and stress-
activated protein kinase) is a key signaling
molecule downstream of p38 MAPK
and ERK and is known to induce
phosphorylation of histone H3 (at Ser10)
(12). In parallel with dexamethasone, we
pretreated ASM cells with inhibitors of p38
MAPK and ERK pathways (using SB203580
and PD98059, respectively) before
stimulation with S1P. S1P rapidly and
robustly induced phosphorylation of MSK1
at (Thr581) within 5 minutes, was sustained
for 10 to 30 minutes, and subsided to basal
levels by 60 minutes (Figures 5A–5C). We
noted subsequent phosphorylation of
histone H3 (at Ser10), with a peak generally
observed at 30 minutes. Pretreatment of
ASM cells with dexamethasone (Figure 5A)
repressed S1P-induced MSK1
phosphorylation and histone H3
activation in a manner similar to those in
cells pretreated with inhibitors of p38
MAPK (Figure 5B) or ERK (Figure 5C).
That is, the temporal kinetics of MSK1
phosphorylation were considerably
abridged, and the degree of activation of
histone H3 at 30 minutes was
substantially repressed. This was
confirmed by densitometry (Figures 5D
and 5E), where dexamethasone,
SB203580, or PD98059 had a significant
effect on S1P-induced MSK1 and histone
H3 phosphorylation (P , 0.05).
Phosphorylated histone H3 contributes to
a relaxed chromatin environment and is
associated with enhanced cytokine
expression in ASM cells (13–14). These
results demonstrate that the repression of
S1P-induced cytokine secretion by
dexamethasone may occur via inhibition
of MSK1-mediated histone H3
phosphorylation by MKP-1.
S1P Induces IL-6 Secretion via
a MSK1-Dependent Pathway, but
Inhibition by Dexamethasone Is Not
Due to Altered Subcellular
Distribution of MSK1
To confirm the important role played by
MSK1 signaling in S1P-induced cytokine
secretion in ASM cells, we knocked down
MSK1 with siRNA and measured the effect
on S1P-induced IL-6 secretion.
Nucleofection of ASM cells with siRNA
against MSK1 substantially reduced MSK1
protein levels in comparison to cells
transfected with scrambled control
(Figure 6A). We then measured the IL-6
secreted into the cellular supernatants and
found that in the absence of MSK1, the
amount of IL-6 secreted by ASM cells in
Figure 3. S1P-induced IL-6 transcriptional regulation is CRE dependent, but dexamethasone does
not inhibit S1P-induced cyclic adenosine monophosphate response-element-binding protein (CREB)
phosphorylation. (A) ASM cells were transfected with the parental construct pIL-6-luc 651, with
a series of constructs in which the consensus binding sites for AP-1, C/EBP, and NF-kB had
been inactivated by site-directed mutagenesis, or with a 59-deletion construct (pIL-6-luc158) in which
the AP-1 and CREB binding sites had been deleted. Cells were growth arrested and treated with
vehicle or S1P (1 mM) for 24 hours. The data represent normalized luciferase activity relative to
vehicle-treated cells (expressed as fold difference). Statistical analysis was performed using the
Student’s unpaired t test. *Significant effect of promoter truncation (P , 0.05). Data are mean 1 SEM
values from n = 10 primary ASM cell lines. (B) Growth-arrested ASM cells pretreated for 1 hour with
vehicle or 100 nM dexamethasone were stimulated with S1P (1 mM) for 0, 5, 10, 30, and 60 minutes.
Cells were lysed and then analyzed by Western blotting using specific antibodies against
phosphorylated (Ser133) and total CREB. Results are representative Western blots (from n = 6 primary
ASM cell lines).
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response to stimulation with S1P was
greatly significantly reduced (P , 0.05)
(Figure 6B).
In cell types apart from ASM,
dexamethasone has been shown to repress
inflammatory gene expression by altering
the subcellular distribution of MSK1 and
inducing translocation of MSK1 from the
nucleus to the cytoplasm (15). To ensure
that this is not the underlying
mechanism, we examined the nuclear
translocation of MSK1 in ASM cells after
dexamethasone pretreatment. MSK1 is
found resident in the nucleus (16), as
confirmed in the vehicle-treated cells
shown in Figure 6C. S1P or
dexamethasone treatment alone did not
alter MSK1 subcellular distribution.
Moreover, the levels of MSK1 in the
nucleus were unchanged by the
pretreatment with dexamethasone before
S1P stimulation.
Dexamethasone-Induced MKP-1
Inhibits S1P-Induced Activation of
MSK1 and Induction of Histone
H3 Phosphorylation
Because the molecular mechanism
responsible for dexamethasone was not due
to redistribution of nuclear MSK1 to the
cytoplasm, we confirmed that the repressive
effects of corticosteroids were due to up-
regulation of the MAPK deactivator
(MKP-1) and attenuation of p38 MAPK
and ERK activation upstream of MSK1
phosphorylation. This was demonstrated
by pretreating cells with triptolide, an
inhibitor of MKP-1 up-regulation (14, 17, 18),
and by observing the effect on downstream
phosphoprotein signaling molecules
responsible for cytokine secretion.
Triptolide pretreatment completely
abrogated MKP-1 protein induced by
dexamethasone 1 S1P at 60 minutes
(Figure 7A). In triptolide-treated cells 30
to 60 minutes after dexamethasone 1 S1P,
where we had previously observed a decline
in MAPK activity as MKP-1 up-regulation
increased, we now demonstrate that
S1P-induced MAPK signaling continues
unabated in the absence of MKP-1. There
are high levels of phosphorylated MSK1
(Thr581) and histone H3 (Ser10) in the
absence of MKP-1 at 60 minutes as
confirmed by densitometry (Figures 7B
and 7C). Taken together, our results
suggest that corticosteroid-induced
MKP-1 controls the extent and duration
of S1P-induced MAPK-driven, MSK1/
histone H3 proinflammatory signaling
pathways to restrain cytokine secretion in
ASM cells.
Discussion
S1P, a bioactive sphingolipid found in
elevated amounts in the airways of
individuals with asthma, has emerged as an
important mediator responsible for airway
inflammation and hyperresponsiveness in
asthma. In this study, we uncover the
molecular pathways underlying S1P-
induced secretion of IL-6 in ASM cells and
perform the first investigation examining
Figure 4. S1P-induced mitogen-activated protein kinase (MAPK) phosphorylation is inhibited by
dexamethasone-induced mitogen-activated protein kinase phosphatase 1 (MKP-1). (A) Growth-
arrested ASM cells pretreated for 1 hour with vehicle or 100 nM Dex were stimulated with S1P (1 mM)
for 0, 5, 10, 30, and 60 minutes. Cells were lysed and then analyzed by Western blotting using
specific antibodies against phosphorylated (Thr180/Tyr182) and total p38 MAPK, phosphorylated
(Thr202/Tyr204) and total ERK, phosphorylated (Thr183/Tyr185) and total c-Jun N-terminal kinase (JNK),
and MKP-1. a-Tubulin was used as the loading control. (A) Representative Western blots. (B)
Densitometric analysis of MKP-1 protein up-regulation expressed as fold increase over 0 minutes.
(C–E) Effect of dexamethasone on S1P-induced p38 MAPK, ERK, and JNK phosphorylation (results
expressed as % S1P-induced phosphorylation at 30 min). Statistical analysis was performed using
two-way ANOVA and Bonferroni’s post-test (B) or Student’s unpaired t test (C–E). *Significant effect
of dexamethasone (P , 0.05). Data are mean 1 SEM values from n = 6 primary ASM cell lines.
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the inhibitory effects of corticosteroids on
S1P-induced ASM synthetic function. Our
results show that dexamethasone inhibits
S1P-induced IL-6 mRNA expression and
protein secretion from ASM cells by
a repressive mechanism independent of the
effects on cAMP/CREB/CRE-dependent
transcriptional pathway, IL-6 mRNA
stability, and MSK1 nuclear relocation.
Rather, our studies reveal that
corticosteroids repress cytokine secretion in
ASM cells via a mechanism dependent on
MKP-1–mediated inhibition of MAPK-
driven MSK1/histone H3 phosphorylation.
S1P is a product of sphingolipid
metabolism (via the action of two
sphingosine kinase [SphK] isoenzymes,
SphK1 and SphK2) and is formed in
multiple cell types in response to numerous
stimuli. The pleiotropic actions of S1P are
mediated via a family of G protein–coupled
receptors, formerly known as EDG
(Endothelial Differentiation Gene)
receptors. Five members of the EDG family,
S1P1 (formerly EDG-1 [19]), S1P2 (EDG-5
[20]), S1P3 (EDG-3 [20]), S1P4 (EDG-6
[21]), and S1P5 (EDG-8 [22]), have been
shown to be S1P receptors. S1P receptor
expression is cell type and species specific,
and most cell types express multiple
receptors for S1P. We have shown that ASM
cells express mRNA for S1P1–4 (1) (S1P5 was
not examined). Because S1P receptors signal
to multiple cellular signaling pathways via
specific G proteins, myriad cellular processes
are activated on activation with S1P as an
extracellular ligand.
Our original observation in 2001 (1)
demonstrated that S1P was found elevated
in the airways of subjects with asthma 24
hours after segmental allergen challenge,
correlated with concomitant increases in
airway eosinophilia, protein influx, and fall
in baseline lung function. The cellular
source of S1P is the mast cell, whereby
cross-linking of FceRI activates SphK
isozymes to phosphorylate sphingosine to
result in the secretion of S1P (23). Over the
past decade, substantial evidence has
emerged to underscore the importance of
S1P-stimulated pathways in the airway cell
functions responsible for the development
of asthma, such as ASM proliferation (1,
24), eosinophil chemotaxis (25), and
contraction of ASM cells (1, 26), fibroblast
cells (27), and guinea pig smooth muscle
strips (28). These in vitro and ex vivo
studies indicate a proasthmatic role for S1P,
although in the course of asthma numerous
other stimuli may activate other
proinflammatory pathways. For this
reason, recent evidence in vivo in murine
models of asthma (2, 3) helps reinforce the
important proasthmatic role played by
S1P. An significant recent study (29)
revealed that a specific inhibitor of SphK1
attenuates airway hyperresponsiveness and
represses airway inflammation in a mast
cell–dependent mouse model of allergic
asthma; this underscores the important
role played by S1P and highlights the
promise of targeting the SphK1 isoform in
asthma.
Figure 5. Dex inhibits S1P-induced activation of mitogen and stress-activated protein kinase 1
(MSK1) and induction of histone H3 phosphorylation. Growth-arrested ASM cells pretreated with
vehicle or Dex (100 nM) for 1 hours (A), vehicle or SB203580 (1 mM) for 30 minutes (B), or vehicle
or PD98059 (10 mM) (C) were stimulated with S1P (1 mM) for 0, 5, 10, 30, and 60 minutes. Cells
were lysed and analyzed by Western blotting using specific antibodies against phosphorylated
(Thr581) and total MSK1 and phosphorylated (Ser10) and total histone H3. (A–C) Representative
Western blots. (D and E) Densitometric analysis of the effect of Dex, SB203580, or PD98059 on S1P-
induced MSK1 (D) or histone H3 (E) phosphorylation (results expressed as % S1P-induced
phosphorylation at 30 min). Statistical analysis was performed using Student’s unpaired t test.
*Significant inhibition (P , 0.05). Data are mean 1 SEM values from n = 4 primary ASM cell lines.
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Thus, because S1P-mediated
proinflammatory and hyperresponsive
functions have been shown to be pivotal in
asthma, S1P and its receptors, as well as
SphK1, have emerged as important
candidates for the development of future
pharmacotherapeutic strategies in asthma
(29–32). Another strategy to reduce the
S1P-induced proinflammatory actions in
asthma is to repress the cellular signaling
pathways responsible for S1P-induced
synthetic function. To this end, in the
current study we demonstrate the
repressive action of the first-line
antiinflammatory medications used in
asthma (i.e., corticosteroids). We show that
the corticosteroid dexamethasone
significantly inhibits S1P-induced IL-6
protein secretion and mRNA expression.
Although many cytokines in addition to IL-
6, including IL-13, IL-4, and IL-5, play
a major role in airway inflammation and
hyperreactivity in asthma, in this study we
have chosen to focus on S1P-induced IL-6
because its secretion from ASM cells was
first reported by us in 2001 (1). As such, IL-
6 secretion can serve as a model system to
delineate the molecular mechanisms
underlying corticosteroid-mediated
repression.
The molecular mechanisms underlying
the repressive effects of corticosteroids on
gene expression are multifactorial (reviewed
in Refs. 33–35). Because an increased
understanding of the molecular
mechanisms by which corticosteroids
suppress airway inflammation in asthma
may identify novel targets for the
development of corticosteroid-sparing
pharmacotherapeutic strategies in the
future, we performed further investigations
to elucidate the mechanism responsible for
the inhibition of S1P-induced IL-6 gene
expression by dexamethasone. Our studies
reveal that some of the more well-
established mechanisms known to be
responsible for corticosteroid action are not
responsible for the inhibition of S1P-
induced IL-6 gene expression. In cell types
other than ASM, corticosteroids can
produce a repressive effect by binding to
the glucocorticoid receptor that then
interacts with other transcription factors,
such as CREB (36). In our study we show
that dexamethasone pretreatment had
no effect on S1P-induced CREB
phosphorylation at Ser133. In addition, we
investigated the subcellular localization of
MSK1 because corticosteroids have been
shown to alter the distribution of this key
downstream effector and repress
inflammatory pathways (15); this
possibility was also excluded.
Our data highlight another important
way in which the corticosteroid-induced
Figure 6. S1P induces IL-6 secretion via a MSK1-dependent pathway, but inhibition by
dexamethasone is not due to altered subcellular distribution of MSK1. (A and B) ASM cells were
transiently transfected using nucleofection with scrambled control or MSK1 siRNA, growth-arrested,
and treated for 24 hours with vehicle or S1P (1 mM). (A) To confirm that MSK1 siRNA reduces
protein levels of MSK1, cells were lysed and immunoblotted for MSK1 using a-tubulin as the loading
control. (B) To demonstrate that S1P induces IL-6 secretion via a MSK1-dependent pathway,
supernatants were removed and IL-6 protein measured by ELISA. (A) Representative Western blot.
(B) Results expressed as % S1P-induced IL-6 secretion in cells transfected with scrambled control
siRNA (mean1SEM values from n = 6 primary ASM cell lines). Statistical analysis was performed
using the Student’s unpaired t test. *Significant decrease in % S1P-induced IL-6 secretion (P, 0.05).
(C) Growth-arrested ASM cells pretreated for 1 hour with vehicle or dexamethasone (100 nM)
and then treated with vehicle or S1P (1 mM) for 30 minutes. Cytoplasmic and nuclear protein extracts
were prepared and MSK1 subcellular distribution measured by Western blotting, compared with
a-tubulin and lamin A/C as loading controls for the cytosolic and nuclear fractions, respectively.
Results are representative Western blots (from n = 3 primary ASM cell lines).
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MKP-1 can repress airway inflammation.
We and others have recently shown that
many of the antiinflammatory actions of
corticosteroids in ASM cells are mediated
via the induction of the endogenous MAPK
inhibitor, MKP-1. MKP-1 has multiple
modes of repression: it acts as a critical
negative feedback effector (4, 14), limiting
the extent and duration of proinflammatory
cellular signaling; it can repress synthetic
function of this immunomodulatory airway
cell type by antiasthma drugs (37–39); and
it can reduce p38 MAPK-mediated mRNA
stability (10). In the current study, we
demonstrate an additional mode of MKP-
1–mediated repression (i.e., via inhibition
of MAPK-driven MSK1/histone H3
phosphorylation). We confirm that S1P can
induce activation of a variety of MAPKs
and that the increase in MKP-1 after
corticosteroid treatment appeared to mirror
the decrease in S1P-induced MAPK
phosphorylation. These results add to the
accumulating evidence in ASM cells,
demonstrating that dexamethasone-
induced MKP-1 shortens the temporal
phosphorylation of MAPKs in response to
TNF-a (10), IL-1b (11), and now S1P. It is
not an effect on S1P-induced IL-6 mRNA
stability that is responsible for the
repression of S1P-induced synthetic
function by corticosteroids; herein we show
that repression may be due to an effect on
chromatin remodeling. We have shown
that by shortening the temporal kinetics of
MAPK-driven MSK1 phosphorylation,
dexamethasone reduces phosphorylation of
histone H3 at Ser10, a key regulatory site
responsible for the promotion of a relaxed
chromatin environment in transcription
(12). The MKP-1 dependence was
confirmed by treatment with triptolide, an
inhibitor of MKP-1 up-regulation, where
repressive effects of corticosteroids were
reversed and the phosphorylation of MSK1/
histone H3 was unrestrained.
S1P-induced IL-6 secretion is
completely inhibited by corticosteroids. We
speculate that this is due to the fact that S1P-
induced IL-6 transcriptional regulation is
NF-kB independent (as demonstrated in
our IL-6 luciferase constructs experiments)
because NF-kB appears refractory to
inhibition by corticosteroids in ASM cells
(40).
Collectively, our results confirm that
S1P, a bioactive sphingolipid found elevated
in asthma, induces synthetic function of the
pivotal airway cell type–ASM. Although
dexamethasone significantly inhibits IL-6
secretion via inhibition of gene expression
at the transcriptional (rather than post-
transcriptional) level, this repression was
not due to inhibition of CREB activation,
an effect of mRNA stability, or MSK1
translocation. Instead we show that by up-
regulating the MAPK deactivator MKP-1,
corticosteroids restrain MAPK-driven
MSK1 activation and histone H3
phosphorylation, proinflammatory
pathways known to control cytokine
expression. Taken together, our study
identifies molecular mechanisms
underlying the antiinflammatory capacity
of corticosteroids to repress pro-remodeling
functions induced by the potent bioactive
sphingolipid in the lung. n
Figure 7. Dex-induced MKP-1 inhibits S1P-induced activation of MSK1 and induction of histone
H3 phosphorylation. Growth-arrested ASM were pretreated with triptolide (1 mM) for 30 minutes,
followed by 1 hour pretreatment with vehicle or Dex (100 nM) and then stimulated with S1P (1 mM)
for 0, 5, 10, 30, and 60 minutes. Cells were lysed and then analyzed by Western blotting using
specific antibodies against MKP-1 (a-tubulin was used as the loading control), phosphorylated
(Thr180/Tyr182) and total p38 MAPK, phosphorylated (Thr202/Tyr204) and total ERK, phosphorylated
(Thr581) and total MSK1, and phosphorylated (Ser10) and total histone H3. (A) Representative Western
blots. (B and C) Densitometric analysis of the effect of triptolide on the repression of S1P-induced
MSK1 (B) or histone H3 (C) phosphorylation by Dex (results expressed as fold increase in
phosphorylation at 60 min). Statistical analysis was performed using Student’s unpaired t test.
*Significant inhibition (P , 0.05). Data are mean 1 SEM values from n = 3 primary ASM cell lines.
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